Electra Therapeutics, Inc. Form SCHEDULE 13D — Sep 25, 2026
OrbiMed entities filed a Schedule 13D disclosing beneficial ownership of 6,885,170 shares, or about 11%, of Electra Therapeutics common stock, following the company's IPO. The stake consists of 5,126,891 shares (8.2%) held by OrbiMed Private Investments VII and 1,758,279 shares (2.8%) held by OrbiMed Genesis Master Fund, plus IPO purchases of 1,333,333 shares at $15.00 each. The filing states the shares were acquired for investment purposes only, with no plans or proposals to seek control, change the board, or pursue an extraordinary corporate transaction. Carl L.
Key figures
- Shares Outstanding
- 62766955
- Genesis shares
- 1758279
- Opi vii shares
- 5126891
- Genesis percent
- 2.8%
- Opi vii percent
- 8.2%
- Ipo purchase price
- $15.00 per share
- Lockup period days
- 180
- Shares purchased in ipo
- 1,333,333 (333,333 by OPI VII + 1,000,000 by Genesis)
- Aggregate percent of class
- 11%
- Registration rights threshold s1
- $15 million
- Registration rights threshold s3
- $10 million
- Aggregate shares beneficially owned
- 6885170
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.